Cardiovascular Risk Reduction and Other Co-Morbidities in Type 2 Diabetes
|
|
- Opal Lawrence
- 5 years ago
- Views:
Transcription
1 Cardiovascular Risk Reduction and Other Co-Morbidities in Type 2 Diabetes Following this presentation, you will be able to: Describe the relationship between major CV risk factors and CVD outcomes Select therapeutic modalities available to practitioners to improve CV risk factors Discuss other co-morbid/microvascular conditions seen in patients with type 2 diabetes Recognize the implications of recent large trials on guiding clinical decisions and targets for blood pressure and lipid abnormalities Explain the role of pharmacologic intervention in the treatment of type 2 diabetes CV = cardiovascular; CVD = cardiovascular disease.
2 Type 2 Diabetes and CVD Type 2 diabetes is considered a CHD equivalent Atherosclerotic complications are responsible for: 80% of mortality among patients with diabetes More than 75% of all hospitalizations for diabetic complications 50% of patients with type 2 diabetes have preexisting CAD One-third of patients presenting with MI have undiagnosed diabetes mellitus CAD = coronary artery disease; CHD = coronary heart disease; CVD = cardiovascular disease; MI = myocardial infarction. Lewis GF. Can J Cardiol. 11(suppl C):24C-28C, 1995; Norhammar A, et.al. Lancet 359; , 2002; NCEP ATP III. Circulation. 2002;106(25):3143; Meigs, et al. Am J Med. 1997;102:38-47.
3 Compared with Individuals Without Diabetes, Patients with Diabetes Have a 2- to 4-Fold Increased Risk of Developing and Dying of CHD CVD Mortality Among Participants with and without DM CHD = coronary heart disease; CVD = cardiovascular disease; DM = diabetes mellitus. Preis, et al. Circulation. 119(13): , 2009.
4 No. events per 100 person- years Absolute Risk of MI Is Higher in Patients with DM Diabetes n = 379,003 No Diabetes n = 9,018,082 Database Diabetes Men Women No diabetes Men Women Age group All lines fitted according to a polynomial equation; R 2 = for each DM = diabetes mellitus; MI = myocardial infarction. Booth GL, et al. Lancet 368:29-36, 2006.
5 T2DM for >15 Years Duration Confers Similar Risk of Fatal CHD as Prior CHD and No Diabetes 20-year Follow-Up of 121,046 Women Aged 30 to 55 Years in Nurses Health Study CHD = coronary heart disease; DM = diabetes mellitus; T2DM = type 2 diabetes mellitus. Hu F, et al. Arch Intern Med. 161: , 2001.
6 Age-standardized Rates of Diabetes Complications: Rates of diabetes-related complications declined between 1990 and 2010 (relative risk reductions): Myocardial infarction -68.8%, death from hyperglycemic crisis -64.4%, end-stage renal disease -28.3%, stroke and amputation ~50% ESRD = end-stage renal disease. Gregg EW, et al. N Engl J Med 370: , 2014.
7 Event Rates/10,000 Adults/Year ESRD = end-stage renal disease. Gregg EW, et al. N Engl J Med 370: , 2014.
8 How Is CAD Different in Diabetes? > CAD extent Multi-vessel disease Distal disease more difficult to revascularize Silent ischemia/mi Younger Women Worse outcomes despite revascularization Increased re-stenosis after PCI even with stents ACB: worse perioperative and long-term outcomes ACB = aortocoronary bypass; CAD = coronary artery disease; MI = myocardial infarction; PCI = percutaneous coronary intervention.
9 Diabetes Mellitus and Factors That May Predispose to Atherosclerosis and Cardiovascular Disease AGE = advanced glycation end-product; CRP = c-reactive protein; DM = diabetes mellitus; HDL = high density lipoprotein; LDL = low density lipoprotein; PA = plasminogen activator; PAI-1 = plasminogen activator inhibitor-1; TGRL = triglyceride-rich lipoprotein. Hayden: Curr Opin Lipidol, (5) , 2000.
10 Abdominal Obesity and Increased Risk of Cardiovascular Events: HOPE Study Adjusted Relative Risk 1.4 Waist circumference (in): 1.29 Tertile 1 Tertile 2 Tertile 3 Men < > Women < > BMI = body mass index; C = cholesterol; CVD = cardiovascular disease; DM = diabetes mellitus; HDL = high density lipoprotein; MI = myocardial infarction. Dagenais GR, et al. Am Heart J. 149(1):54-60, Jan CVD death MI All-cause deaths *Adjusted for BMI, age, smoking, sex, CVD disease, DM, HDL-cholesterol, total-c
11 Adipose Tissue in Obesity Lean Obese Després J-P. Eur Heart J Suppl. 8(suppl B):B4-12, Gustafson. Arterioscler Thromb Vasc Biol, 27(11): , 2007.
12 Systemic Effects of Inflammation in Insulin Resistance and Cardiovascular Disease EC = endothelial cells; FFA = free fatty acid. Shoelson, et al. J. Clin. Invest. 116: , 2006.
13 Strategies For Reducing Macrovascular Complications Prevention proven by intervention Hyperglycemia Hypertension Dyslipidemia Antiplatelet therapy Smoking Cessation Exercise
14 Type 2 Diabetes: A1C Predicts CHD CHD Mortality Incidence (%) in 3.5 Years * All CHD Events Incidence (%) in 3.5 Years ** 0 Low <6% Middle 6-7.9% High >7.9% *P<0.01 vs lowest tertile 0 Low <6% Middle 6-7.9% High >7.9% **P<0.05 vs lowest tertile A1C = glycated hemoglobin; CHD = coronary heart disease. Kuusisto J, et al. Diabetes. 43: , 1994.
15
16 ACCORD: Treatment Effects on Glucose Control Standard therapy A1C (%) Intensive therapy Time (years) A1C = glycated hemoglobin. ACCORD Study Group. N Engl J Med 358: , 2008.
17 ACCORD: Treatment Effect on Primary Outcome 25 Patients with events (%) HR 0.90 ( ) P = 0.16 Standard therapy Intensive therapy 2.29%/yr 2.11%/yr Time (years) HR = heart rate. ACCORD Study Group. N Engl J Med 358: , 2008.
18 ADVANCE: Treatment Effect on Glucose Control Mean A1C (%) Standard control P < Intensive control Follow-up (months) A1C = glycated hemoglobin. ADVANCE Collaborative Group. N Engl J Med 358: , 2008.
19 ADVANCE: Treatment Effect on Primary Macrovascular Outcome CV Death, MI, Stroke 25 Cumulative incidence (%) HR 0.94 ( ) P = 0.32 Standard control Intensive control Follow-up (months) CV = cardiovascular; HR = heart rate; MI = myocardial infarction. ADVANCE Collaborative Group. N Engl J Med 358: , 2008.
20 A1C (%) VADT-Median A1C +/- IQR STD INT Baseline 1 year 2 years 3 years 4 years 5 years 6 years Years on Study A1C = glycated hemoglobin; INT = intensive control; IQR = interquartile range; STD = standard control; VADT = Veterans Affairs Diabetes Trial. VADT Study Group. N Engl J Med 360: , 2009.
21 Proportion free of primary outcome VADT Primary Outcome 1.0 Time to primary outcome Hazard Ratio & CI (0.728, 1.036) P= Follow-up time (years) VADT = Veterans Affairs Diabetes Trial. VADT Study Group. N Engl J Med 360: , 2009.
22 Glycosylated hemoglobin (Percent) A1C During DCCT and EDIC Observation DCCT Intervention Conventional - mean A1C 9.1 % Training EDIC Observation Conventional - mean A1C 8.2 % 8 7 Intensive - mean A1C 8.0 % 6 Intensive - mean A1C 7.2 % Study year A1C = glycated hemoglobin; DCCT = Diabetes Control and Complications Trial; EDIC = Epidemiology of Diabetes Interventions and Complications. Nathan DM, et al. N Engl J Med 353: , 2005.
23 Cumulative incidence of any predefined cardiovascular outcome Cumulative Incidence of the First of Any Predefined Cardiovascular Disease Outcomes No. at Risk Risk reduction 42% 95% CI: 9, 63 Log-rank P = Years since entry Conventional treatment Intensive treatment Intensive Conventional Nathan DM, et al. N Engl J Med 353: , 2005.
24 Glucose Control and CHD Events ACCORD = Action to Control Cardiovascular Risk in Diabetes; ADVANCE = Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation; CHD = coronary heart disease; PROactive = Prospective Pioglitazone Clinical Trial in Macrovascular Events; UKPDS = United Kingdom Prospective Diabetes Study Group; VADT = Veterans Affairs Diabetes Trial. Ray KK, et al. Lancet. 373: , 2009.
25 Strategies for Reducing Macrovascular Complications Prevention proven by intervention Hyperglycemia Hypertension Dyslipidemia Antiplatelet therapy Smoking Cessation Exercise
26 CV mortality rate Per 10,000 person-years Association of SBP and CV Mortality in Men with T2DM No diabetes Diabetes < SBP (mmhg) 200 CV = cardiovascular; SBP = systolic blood pressure; T2DM = type 2 diabetes mellitus. Stamler J, et al. Diabetes Care. 16: , 1993.
27 Patients with events (%) Hypertension in Diabetes, UKPDS Less tight control (mean BP 154/87 mmhg) Tight control (mean BP 144/82 mmhg) Tight BP control: 24% reduction of events (95% CI 8-38) UKPDS Study Group. BMJ 317:703-13, Years from randomization BP = blood pressure; UKPDS = United Kingdom Prospective Diabetes Study Group.
28 % of patients Effect of Ramipril on Combined Outcome (MI, Stroke, Death) % Risk reduction 25% Risk reduction Placebo Ramipril Placebo Ramipril No diabetes, n=5720 Diabetes, n=3577 MI = myocardial infarction. The Lancet. 2000; 355(9200): Yusuf S, et al. NEJM. 2000:342(3):
29 Risk Reduction (%) Effect of Intensive BP Lowering on Risk of Microand Macrovascular Complications: UKPDS 0 Myocardial infarction Any diabetesrelated endpoint Diabetesrelated death Retinopathy Renal failure Stroke Vision deterioration Heart failure Benefits of 144/82 mmhg vs 154/87 mmhg -56 BP = blood pressure; UKPDS = United Kingdom Prospective Diabetes Study Group. UKPDS Group. UKPDS 38. BMJ. 317: , 1998.
30 Guideline Recommendations for Uncomplicated and Complicated Hypertension Type of hypertension BP goal (mmhg) Uncomplicated <140/90 Complicated Diabetes mellitus <130/80 Kidney disease <130/80* Other high risk (stroke, MI) <130/80 *Lower if proteinuria is >1 g/day. BP = blood pressure; MI = myocardial infarction. Chobanian, et al. Hypertension. 42: , Garber AJ, et al. Endocr Pract. 19(suppl 2):1-48, Handelsman Y, et al. Endocr Pract. 17(suppl 2):1-53, Torre JJ, et al. Endocr Pract. 12: , 2006.
31 AACE = American Association of Clinical Endocrinologists Garber AJ et al. Endocr Pract. 2017,doi: /EP CS
32 Strategies for Reducing Macrovascular Complications Prevention proven by intervention Hyperglycemia Hypertension Dyslipidemia Antiplatelet therapy Smoking Cessation Exercise
33 Percent 60 Diabetes and Lipid Extremes Framingham Offspring Men P<0.001 Diabetes No diabetes 30 P< P< HDL-C<35 Total-C 240+ LDL-C 160+ Trig 250+ HDL-C<35 Total-C 240+ mg/dl C = cholesterol; HDL-C = high density lipoprotein-cholesterol; LDL-C = low density lipoprotein-cholesterol. Siegel Metabolism 96:1267, 1996.
34 Priorities for Lipid Levels in Adult Patients with Diabetes LDL cholesterol lowering Statin at maximally tolerated dose HDL cholesterol raising Behavior: weight loss, physical activity, smoking cessation Glycemic control Triglyceride lowering Glycemic control first priority Fibric acid derivative (gemfibrozil, fenofibrate) Statins at high dose also have some TG lowering Niacin or high-dose omega-3 fatty acids Triglyceride goal presently <150 mg/dl HDL = high density lipoprotein; LDL = low density lipoprotein; TG = triglyceride. Handelsman Y et al. Endocr Pract. Vol 21; (Suppl 1). 2015
35 ACC/AHA 2013 Recommendations CVD Primary Prevention U.S. Adults Group Diabetes Mellitus ACC/AHA 2013 All individuals >40 y/o with diabetes are considered high CVD risk Rx high-potency statin No fixed LDL-C targets ACC = American College of Cardiology; AHA = American Heart Association; CVD = cardiovascular disease; LDL-C = low density lipoprotein-cholesterol. Goff DC et al. JACC Vol. 63; No. 25, 2014:
36 Statin Therapy in Diabetes American Diabetes Association 2016 Age (years) Risk Factors Statin Dose Lipid Monitoring <40 None ASCVD risk factor(s)** ASCVD*** No medication Moderate or high High Yearly or as needed >75 ACS = acute coronary syndrome; ASCVD = atherosclerotic cardiovascular disease; CVD = cardiovascular disease; LDL = low density lipoprotein; LDL-C = low density lipoprotein-cholesterol. ADA Diabetes Care 38:S63, None ASCVD risk factors ASCVD ACS and LDL> 50 mg/dl* None CVD risk factors Overt CVD ACS and LDL>50 mg/dl* * On basis of IMPROVE-IT subgroup ** LDL-C>100 mg/dl, hypertension, smoking, overweight or obesity Moderate High High Moderate + Ezetimibe Moderate Moderate or high High Moderate + Ezetimibe To monitor adherence To monitor adherence
37 Intensity of Statin Therapy (Doses in mg/day) Low-intensity daily statin Reduce LDL-C <30% Simvastatin 10 Pravastatin Lovastatin 20 Fluvastatin Pitavastatin 1 Boldface type indicates specific statins and doses that were evaluated in RCTs included in CQ1, CQ2, and the Cholesterol Treatment Trialists 2010 meta-analysis included in CQ3. All of these RCTs demonstrated a reduction in major cardiovascular events. Italic type indicates statins and doses that have been approved by the FDA but were not tested in the RCTs reviewed. Individual responses to statin therapy varied in the RCTs and should be expected to vary in clinical practice. There might be a biological basis for a less-than-average response. Evidence from 1 RCT only: down-titration if unable to tolerate atorvastatin 80 mg in the IDEAL (Incremental Decrease through Aggressive Lipid Lowering) study. Although simvastatin 80 mg was evaluated in RCTs, initiation of simvastatin 80 mg or titration to 80 mg is not recommended by the FDA because of the increased risk of myopathy, including rhabdomyolysis. BID indicates twice daily; CQ, critical question; FDA, Food and Drug Administration; LDL-C, low-density lipoprotein cholesterol; and RCTs, randomized controlled trials. Stone NJ et al. Circulation. 2014;129[suppl 2]:S1-S45 Moderate-intensity daily statin Reduce LDL-C 30% to <50% Atorvastatin Rosuvastatin 5-10 Simvastatin Pravastatin Lovastatin 40 Fluvastatin XL 80 Fluvastatin 40 BID Pitavastatin 2-4 High-intensity daily statin Reduce LDL-C >50% Atorvastatin (40 )-80 Rosuvastatin 20-40
38 Cholesterol Lowering in High Risk Patients: The Heart Protection Study LDL lowering resulted in 22% reduction in CVD events across all LDL categories CHD = coronary heart disease; CVD = cardiovascular disease; LDL = low density lipoprotein; MI = myocardial infarction. HPS Collaborative Group. Lancet. 2002;360:7-22.
39 Statins and CVD in Patients with Diabetes: CTT Meta-analysis CTT = Cholesterol Trialists Collaboration; CVD = cardiovascular disease; RR = rate ratio. Cholesterol Treatment Trialists. Lancet 371: 117, 2008.
40 AACE Dyslipidemia Management Algorithm When atherogenic markers are not at goal: To lower LDL-C: To lower non-hdl-c, TG: To lower APO-B, LDL-P: Intensify statin and/or, add ezetimibe and/or PCSK9 and/or colesevelam and/or niacin Intensify statin and/or Rx-grade Omega-3 fatty acid and/or fibrates and/or niacin Intensify statin and/or add ezetimibe and/or PCSK9 and/or colesevelam AACE = American Association of Clinical Endocrinologists; APO-B = apolipoprotein-b; HDL-C = high density lipoprotein-cholesterol; LDL-C = low density lipoprotein-cholesterol; LDL-P = low density lipoprotein-particles; PCSK9 = proprotein convertase subtilisin/kexin type 9; TG = triglyceride. Garber et al. Endocr Pract. 2016; Vol 22 No. 1:
41 Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Reduce LDL-C levels Have been shown to reduce cardiovascular endpoints LDL-C = low density lipoprotein-cholesterol; PCSK9 = proprotein convertase subtilisin/kexin type 9. New Eng J Med 372: , New Eng J Med 372: , 2015.
42 The Role of PCSK9 in the Regulation of LDL Receptor Expression For illustration purposes only LDL = low density lipoprotein; LDL-R = low density lipoprotein receptor; PCSK9 = proprotein convertase subtilisin/kexin type 9; SREBP = sterol response element binding protein. Lambert G, et al.. J Lipid Res. 2012; Vol 53:
43 PCSK9 Inhibitors IND1ICATIONS Adjunct to diet and maximally tolerated statin therapy in adults Heterozygous familial hypercholesterolemia Clinical atherosclerotic CV disease who require additional lowering of LDL-C SIDE EFFECTS Injection site reactions; myalgias; neurocognitive (confusion, impaired memory); nasopharyngitis; upper respiratory tract infection; back pain; influenza. DOSAGE: Alirocumab (Praluent R ) Evolucumab (Repatha R ) 75 mg/2 weeks or 150 mg /2 weeks 140 mg /2 weeks or 420mg/month CV = cardiovascular; LDL-C = low density lipoprotein-cholesterol; PCSK9 = proprotein convertase subtilisin/kexin type 9.
44 HeFH or high CV risk patients on maximally tolerated statin ± other LLT, with LDL >70 mg/dl Least-squares mean difference, baseline to week 24 Apo B=apolipoprotein B; CV=cardiovascular; DM=diabetes mellitus; HeFH=heterozygous familial hypercholesterolemia; Lp(a)= lipoprotein(a); LDL=low density lipoprotein; LLT=lipidlowering therapy Alirocumab in Individuals with and without Diabetes: ODYSSEY Study DM Entire Cohort no DM LDL-C Non-HDL-C Apo B Lp(a) Colhoun HM, et al. Presented September 19, 2015 EASD Stockholm, Sweden
45 Preliminary Analysis, ODYSSEY Long-term Study: Treatment-emergent MACE at 78 Weeks with Alirocumab HeFH or high CV risk patients on maximally tolerated statin ± other LLT, with LDL >70 mg/dl (baseline LDL 123 MACE = Major CV Events confirmed by adjudication: cardiac death, non-fatal MI, fatal/non-fatal stroke, unstable angina requiring hospitalization Percent 2.8 Placebo mg/dl) HR 0.52 MACE (0.31 to Events 0.90) n=1,489 n=838 n=2,341 HR 0.47 (0.22 to 1.00) 1.3 Alirocumab 150 mg q2wks 1.7 HR 0.58 (0.27 to 1.25) 2 Overall pop. No Diabetes Colhoun HM, et al. Presented at September 19, 2015 EASD Meeting, Stockholm, Sweden CV=cardiovascular; DM=diabetes mellitus; HeFH=heterozygous familial hypercholesterolemia; LDL=low density lipoprotein; LLT=lipidlowering therapy; MI=myocardial infarction; RRR=relative risk ratio Diabetes LDL in entire cohort by 62% ( mg/dl); CV event RRR by 48% LDL in patients without diabetes by 63% ( mg/dl); CV event RRR 53% LDL in diabetes group by 59% ( mg/dl) & CV event RRR 42%
46 Lipid Changes, Baseline To 12 Weeks: Evolocumab vs Ezetimibe or Placebo LDL TRIG Non-HDL Lp(a) HDL HDL=high-density lipoprotein; LDL=low density lipoprotein; Lp (a)=lipoprotein(a) TRIG=triglycerides Sattar M, et al. Lancet Diab Endocrinol. 2016:4(5)
47 Strategies for Reducing Macrovascular Complications Prevention proven by intervention Hyperglycemia Hypertension Dyslipidemia Antiplatelet therapy Smoking Cessation Exercise
48 What About ASA for 1⁰ Prevention of CVD? Included: 6 studies, N = 10,117 participants ASA = acetylsalicylic acid (aspirin); CVD = cardiovascular disease. De Berardis G, et al. BMJ 339:b4531, 2009.
49 ASA for 1⁰ Prevention in Diabetes: Meta Analysis of 6 Studies (N=10,117) Major CV events JPAD POPADAD WHS PPP ETDRS Total No. of events/no. in group ASA Control/placebo RR (95% CI) RR (95% CI) 68/ /638 58/514 20/ / / / /638 62/513 22/ / / ( ) 0.97 ( ) 0.90 ( ) 0.90 ( ) 0.90 ( ) 0.90 ( ) No overall benefit for: Major CV events MI Stroke CV mortality All-cause mortality Myocardial infarction JPAD POPADAD WHS PPP ETDRS PHS Total Stroke JPAD POPADAD WHS PPP ETDRS Total 28/ /638 36/514 5/ / / / / /638 15/514 9/519 92/ / / /638 24/513 10/ / / / / /638 31/513 10/512 78/ / ( ) 1.10 ( ) 1.48 ( ) 0.49 ( ) 0.82 ( ) 0.40 ( ) 0.86 ( ) 0.89 ( ) 0.74 ( ) 0.46 ( ) 0.89 ( ) 1.17 ( ) 0.83 ( ) ASA = acetylsalicylic acid (aspirin); CV = cardiovascular; ETDRS = Early Treatment Diabetic Retinopathy Study; JPAD = Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes; MI = myocardial infarction; PHS = Physicians Health Study; POPADAD = Prevention of Progression of Arterial Disease and Diabetes; PPP = Primary Prevention Project; RR = rate ratio; WHS = Women s Health Study. De Berardis G, et al. BMJ 339:b4531, Death from CV causes JPAD POPADAD PPP ETDRS Total All-cause mortality JPAD POPADAD PPP ETDRS Total 1/ /638 10/ / / / /638 25/ / / / /638 8/ / / / /638 20/ / / Favors ASA 0.10 ( ) 1.23 ( ) 1.23 ( ) 0.87 ( ) 0.94 ( ) 0.90 ( ) 0.93 ( ) 1.23 ( ) 0.91 ( ) 0.93 ( ) 2 8 Favors control/placebo
50 Antiplatelet Agents in Diabetes: 2013 Primary prevention ( mg/day) Type 1 or type 2 diabetes at increased CV risk (10-year risk >10%) Men >50 years of age or women >60 years with 1+ additional major risk factor Family history of CVD, HTN, smoking, dyslipidemia, or albuminuria Not sufficient evidence to recommend aspirin for primary prevention in lower-risk individuals Secondary prevention ( mg/day) Use aspirin therapy as a secondary prevention strategy in those with diabetes with a history of CVD CV = cardiovascular; CVD = cardiovascular disease; HTN = hypertension. American Diabetes Association. Diabetes Care. 36(Suppl 1):S11-66, Jan 2013.
51 ASA Not Routinely Recommended for First- Degree CVD Prevention in Patients with Diabetes Insufficient evidence to support use of ASA for primary prevention Risk of bleeding CVD protection ASA = acetylsalicylic acid (aspirin); CVD = cardiovascular disease.
52 STENO-2
53 STENO-2: Intensive Group Achieved Targets BP = blood pressure. Gaede, et al. NEJM. 348; , 2003.
54 STENO-2: Intensive Group Had Improved CV Outcomes P = Any CV event Conventional therapy Intensive therapy 53 % RRR NNT = Months of Follow-up CV = cardiovascular; NNT = number needed to treat; RRR = relative risk reduction. Gaede, et al. NEJM. 348; , 2003.
55 Gaede, et al. NEJM. 348; , STENO 2: Microvascular Disease
56 STENO 2: 21-Year Follow-up, Death, or CVD Events Median survival was 7.9 years longer in intensive vs conventional group CVD = cardiovascular disease Gaede, et al. Diabetologia. 2016;59:
57 The Prevalence of U.S. Adults with Diabetes Achieving A1C, Blood Pressure, and LDL-C Goals: : NHANES Percent (%) A1C<7.0% BP<130/80 LDL<100mg/dL All 3 at Goal Still a long way to go A1C = glycated hemoglobin; BP = blood pressure; LDL = low density lipoprotein; LDL-C = low density lipoprotein-cholesterol; NHANES = National Health and Nutrition Examination Survey. Casagrande SS, Cowie CC, Fradkin JE, Rust KF, Saydah SH. Diabetes Care 36: , 2013.
58 Treating the ABCs Reduces Diabetic Complications Strategy Blood glucose control (A1C) Blood pressure control Complication Reduction of Complication Myocardial infarction 16% 1 Cardiovascular disease Heart failure Stroke Diabetes-related deaths 51% 2 56% 3 44% 3 32% 3 Lipid control (Cardiovascular) Coronary heart disease mortality Major coronary heart disease event Any atherosclerotic event Cerebrovascular disease event 35% 4 55% 5 37% 5 53% 4 1 UKPDS Study Group (UKPDS 33). Lancet. 352: , Hansson L, et al. Lancet. 351: , UKPDS Study Group (UKPDS 38). BMJ. 317: , Grover SA, et al. Circulation. 102: , Pyŏrälä K, et al. Diabetes Care. 20: , 1997.
59
Cardiovascular Risk Reduction and Other Co-Morbidities in Type 2 Diabetes
Cardiovascular Risk Reduction and Other Co-Morbidities in Type 2 Diabetes Following this presentation, you will be able to: Describe the relationship between major CV risk factors and CVD outcomes Select
More informationCardiovascular Risk Reduction and Other Co-Morbidities in Type 2 Diabetes
Cardiovascular Risk Reduction and Other Co-Morbidities in Type 2 Diabetes May 20, 2017 AACE Diabetes Day for Primary Care Physicians Jorge Plutzky, MD Director, Preventive Cardiology Cardiovascular Division
More informationCardiovascular Risk Reduction and Other Co-morbidities in Type 2 Diabetes
Cardiovascular Risk Reduction and Other Co-morbidities in Type 2 Diabetes Following this presentation, you will be able to: Describe the relationship between major CV risk factors and CVD outcomes Select
More informationCardiovascular Risk Reduction and Other Co-morbidities in Type 2 Diabetes
Cardiovascular Risk Reduction and Other Co-morbidities in Type 2 Diabetes Following this presentation, you will be able to: Describe the relationship between major CV risk factors and CVD outcomes Select
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More information4 th and Goal To Go How Low Should We Go? :
4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationPCSK9 Agents Drug Class Prior Authorization Protocol
PCSK9 Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationWhat do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationDrug Class Monograph
Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationDavid Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationBlood Pressure Treatment Goals
Blood Pressure Treatment Goals Kenneth Izuora, MD, MBA, FACE Associate Professor UNLV School of Medicine November 18, 2017 Learning Objectives Discuss the recent studies on treating hypertension Review
More informationMacrovascular Disease in Diabetes
Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based
More informationGuidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AMERICAN COLLEGE OF ENDOCRINOLOGY Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease Writing Committee Chair: Paul S. Jellinger,
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationAccelerated atherosclerosis begins years prior to the diagnosis of diabetes
Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationLipid Guidelines Who, What, and How Low. Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute
Lipid Guidelines Who, What, and How Low Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute Disclosures! None Objectives! List factors used in screening for dyslipidemia
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationGet a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management
Get a Statin or Not? Treatment Strategies in Dyslipidemia Management Michelle Chu, PharmD, BCACP, CDE Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Sahar Dagher, PharmD Virtual Care
More informationA New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies
A New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies BRODY MAACK, PHARMD, BCACP, CTTS Objectives 1. Review current guidelines regarding use of statin medications in the treatment and prevention
More informationModern Lipid Management:
Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)
More informationPCSK9 Inhibitors: Promise or Pitfall?
PCSK9 Inhibitors: Promise or Pitfall? Tracy Harlan, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics tracy harlan@uiowa.edu Tracy Harlan does not have any actual or potential
More informationNovel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy
LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationWhat Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment?
What Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment? Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director, Prevention Intervention Center University
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationDiabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center
Diabetes and Heart Disease Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center No conflicts of interest or financial relationships to disclose. 2 What s the problem??
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationLipids & Hypertension Update
Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual
More informationDiabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018
Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More informationLatest Guidelines for Lipid Management
Latest Guidelines for Lipid Management Goals Recognize the differences between different guidelines Understand the effective strategies to tailor lipid lowering therapies based on evidence and guideline
More informationThe Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
More informationCV Risk Management in Diabetes Mellitus
CV Risk Management in Diabetes Mellitus J R Minkoff MD, FACP Endocrinology Clinical Professor of Family and Community Medicine University of California, San Francisco Mr. B 40 y/o Latino male c/o fatigue,
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2062-8 Program Prior Authorization/Medical Necessity Medication Praluent (alirocumab) P&T Approval Date 5/2015, 8/2015, 9/2015,
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2063-8 Program Prior Authorization/Medical Necessity Medication Repatha (evolocumab) P&T Approval Date 5/2015, 9/2015, 11/2015,
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationHow to Handle Statin Intolerance in the High Risk Patient
How to Handle Statin Intolerance in the High Risk Patient Thomas D. Conley, MD FACC FSCAI Disclosures: None 1 Definition of High Risk Primary Prevention ASCVD Risk Calculator Adults >21 yrs, LDL 190 mg/dl
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More informationHyperlipidemia: Past and Present. Rebecca Khaimova, PharmD The Brooklyn Hospital Center
Hyperlipidemia: Past and Present Rebecca Khaimova, PharmD The Brooklyn Hospital Center Rkhaimova@tbh.org Conflicts of Interest None to disclose Learning Objectives for Pharmacist Describe the pathophysiology
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationNon-Statin Lipid-Lowering Agents M Holler - Last updated: 10/2016
Drug/Class Cholestyramine (Questran) Bile acid sequestrant Generic? Lipid Effects Y/N (monotherapy) Y LDL : 9% (4 g to 8 ; 21% (16 g to 20 ; 23% to 28% (>20 HDL : 4% to 8% (16 to 24 TG : 11% to 28% (4
More informationLipids What s new? Meera Jain, MD Providence Portland Medical Center
Lipids 2016- What s new? Meera Jain, MD Providence Portland Medical Center 1 Can I trust the ASCVD risk calculator? Do harms outweigh benefits in primary prevention? Is there anything besides a statin?
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationSESSION 3 11 AM 12:30 PM
SESSION 3 11 AM 12:30 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationReducing Cardiovascular Risk Through Non-Statins. Kim K. Birtcher, PharmD Joseph Saseen, PharmD
Reducing Cardiovascular Risk Through Non-Statins Kim K. Birtcher, PharmD Joseph Saseen, PharmD Target Audience: Pharmacists ACPE#: 0202-0000-18-049-L01-P Activity Type: Application-based This activity
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationManagement of Cardiovascular Disease in Diabetes
Management of Cardiovascular Disease in Diabetes Radha J. Sarma, MBBS, FACP. FACC. FAHA. FASE Professor of Internal Medicine Western University of Health Sciences. Director, Heart and Vascular Center Western
More information